The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation

Stefan O Ciurea, Monzr M Al Malki, Piyanuch Kongtim, Ephraim J Fuchs, Leo Luznik, Xiao-Jun Huang, Fabio Ciceri, Franco Locatelli, Franco Aversa, Luca Castagna, Andrea Bacigalupo, Massimo Martelli, Didier Blaise, Patrick Ben Soussan, Yolande Arnault, Rupert Handgretinger, Denis-Claude Roy, Paul V O'Donnell, Asad Bashey, Scott SolomonRizwan Romee, Jorge Gayoso, Hillard M Lazarus, Karen Ballen, Bipin N Savani, Mohamad Mohty, Arnon Nagler

Research output: Contribution to journalReview article

Abstract

The number of HLA-haploidentical hematopoietic cell transplants continues to increase worldwide due to recent improvements in outcomes, allowing more patients with hematological malignancies and non-malignant disorders to benefit from this procedure and have a chance to cure their disease. Despite these encouraging results, questions remain as multiple donors are usually available for transplantation, and choosing the best HLA-haploidentical donor for transplantation remains a challenge. Several approaches to haploidentical transplantation have been developed over time and, based on the graft received, can be grouped as follows: T-cell depleted haploidentical transplants, either complete or partial, or with T-cell replete grafts, performed with post-transplant cyclophosphamide-based graft-versus-host disease (GVHD) prophylaxis, or G-CSF-primed bone marrow graft and enhanced GVHD prophylaxis. Carefully selecting the donor can help optimize transplant outcomes for recipients of haploidentical donor transplants. Variables usually considered in the donor selection include presence of donor-specific antibodies in the recipient, donor age, donor/recipient gender and ABO combinations, and immunogenic variables, such as natural killer cell alloreactivity or KIR haplotype. Here we provide a comprehensive review of available evidence for selecting haploidentical donors for transplantation, and summarize the recommendations from the European Society for Blood and Marrow Transplantation (EBMT) on donor selection for different transplant platforms.

Original languageEnglish
JournalBone Marrow Transplantation
DOIs
Publication statusE-pub ahead of print - Mar 4 2019

Fingerprint

Donor Selection
Cell Transplantation
Transplantation
Bone Marrow
Tissue Donors
Transplants
Graft vs Host Disease
T-Lymphocytes
Granulocyte Colony-Stimulating Factor
Hematologic Neoplasms
Natural Killer Cells
Cyclophosphamide
Haplotypes
Antibodies

Cite this

The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. / Ciurea, Stefan O; Al Malki, Monzr M; Kongtim, Piyanuch; Fuchs, Ephraim J; Luznik, Leo; Huang, Xiao-Jun; Ciceri, Fabio; Locatelli, Franco; Aversa, Franco; Castagna, Luca; Bacigalupo, Andrea; Martelli, Massimo; Blaise, Didier; Ben Soussan, Patrick; Arnault, Yolande; Handgretinger, Rupert; Roy, Denis-Claude; O'Donnell, Paul V; Bashey, Asad; Solomon, Scott; Romee, Rizwan; Gayoso, Jorge; Lazarus, Hillard M; Ballen, Karen; Savani, Bipin N; Mohty, Mohamad; Nagler, Arnon.

In: Bone Marrow Transplantation, 04.03.2019.

Research output: Contribution to journalReview article

Ciurea, SO, Al Malki, MM, Kongtim, P, Fuchs, EJ, Luznik, L, Huang, X-J, Ciceri, F, Locatelli, F, Aversa, F, Castagna, L, Bacigalupo, A, Martelli, M, Blaise, D, Ben Soussan, P, Arnault, Y, Handgretinger, R, Roy, D-C, O'Donnell, PV, Bashey, A, Solomon, S, Romee, R, Gayoso, J, Lazarus, HM, Ballen, K, Savani, BN, Mohty, M & Nagler, A 2019, 'The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation', Bone Marrow Transplantation. https://doi.org/10.1038/s41409-019-0499-z
Ciurea, Stefan O ; Al Malki, Monzr M ; Kongtim, Piyanuch ; Fuchs, Ephraim J ; Luznik, Leo ; Huang, Xiao-Jun ; Ciceri, Fabio ; Locatelli, Franco ; Aversa, Franco ; Castagna, Luca ; Bacigalupo, Andrea ; Martelli, Massimo ; Blaise, Didier ; Ben Soussan, Patrick ; Arnault, Yolande ; Handgretinger, Rupert ; Roy, Denis-Claude ; O'Donnell, Paul V ; Bashey, Asad ; Solomon, Scott ; Romee, Rizwan ; Gayoso, Jorge ; Lazarus, Hillard M ; Ballen, Karen ; Savani, Bipin N ; Mohty, Mohamad ; Nagler, Arnon. / The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. In: Bone Marrow Transplantation. 2019.
@article{0ed7b48870464ba5b9f0bc1440b65c01,
title = "The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation",
abstract = "The number of HLA-haploidentical hematopoietic cell transplants continues to increase worldwide due to recent improvements in outcomes, allowing more patients with hematological malignancies and non-malignant disorders to benefit from this procedure and have a chance to cure their disease. Despite these encouraging results, questions remain as multiple donors are usually available for transplantation, and choosing the best HLA-haploidentical donor for transplantation remains a challenge. Several approaches to haploidentical transplantation have been developed over time and, based on the graft received, can be grouped as follows: T-cell depleted haploidentical transplants, either complete or partial, or with T-cell replete grafts, performed with post-transplant cyclophosphamide-based graft-versus-host disease (GVHD) prophylaxis, or G-CSF-primed bone marrow graft and enhanced GVHD prophylaxis. Carefully selecting the donor can help optimize transplant outcomes for recipients of haploidentical donor transplants. Variables usually considered in the donor selection include presence of donor-specific antibodies in the recipient, donor age, donor/recipient gender and ABO combinations, and immunogenic variables, such as natural killer cell alloreactivity or KIR haplotype. Here we provide a comprehensive review of available evidence for selecting haploidentical donors for transplantation, and summarize the recommendations from the European Society for Blood and Marrow Transplantation (EBMT) on donor selection for different transplant platforms.",
author = "Ciurea, {Stefan O} and {Al Malki}, {Monzr M} and Piyanuch Kongtim and Fuchs, {Ephraim J} and Leo Luznik and Xiao-Jun Huang and Fabio Ciceri and Franco Locatelli and Franco Aversa and Luca Castagna and Andrea Bacigalupo and Massimo Martelli and Didier Blaise and {Ben Soussan}, Patrick and Yolande Arnault and Rupert Handgretinger and Denis-Claude Roy and O'Donnell, {Paul V} and Asad Bashey and Scott Solomon and Rizwan Romee and Jorge Gayoso and Lazarus, {Hillard M} and Karen Ballen and Savani, {Bipin N} and Mohamad Mohty and Arnon Nagler",
year = "2019",
month = "3",
day = "4",
doi = "10.1038/s41409-019-0499-z",
language = "English",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation

AU - Ciurea, Stefan O

AU - Al Malki, Monzr M

AU - Kongtim, Piyanuch

AU - Fuchs, Ephraim J

AU - Luznik, Leo

AU - Huang, Xiao-Jun

AU - Ciceri, Fabio

AU - Locatelli, Franco

AU - Aversa, Franco

AU - Castagna, Luca

AU - Bacigalupo, Andrea

AU - Martelli, Massimo

AU - Blaise, Didier

AU - Ben Soussan, Patrick

AU - Arnault, Yolande

AU - Handgretinger, Rupert

AU - Roy, Denis-Claude

AU - O'Donnell, Paul V

AU - Bashey, Asad

AU - Solomon, Scott

AU - Romee, Rizwan

AU - Gayoso, Jorge

AU - Lazarus, Hillard M

AU - Ballen, Karen

AU - Savani, Bipin N

AU - Mohty, Mohamad

AU - Nagler, Arnon

PY - 2019/3/4

Y1 - 2019/3/4

N2 - The number of HLA-haploidentical hematopoietic cell transplants continues to increase worldwide due to recent improvements in outcomes, allowing more patients with hematological malignancies and non-malignant disorders to benefit from this procedure and have a chance to cure their disease. Despite these encouraging results, questions remain as multiple donors are usually available for transplantation, and choosing the best HLA-haploidentical donor for transplantation remains a challenge. Several approaches to haploidentical transplantation have been developed over time and, based on the graft received, can be grouped as follows: T-cell depleted haploidentical transplants, either complete or partial, or with T-cell replete grafts, performed with post-transplant cyclophosphamide-based graft-versus-host disease (GVHD) prophylaxis, or G-CSF-primed bone marrow graft and enhanced GVHD prophylaxis. Carefully selecting the donor can help optimize transplant outcomes for recipients of haploidentical donor transplants. Variables usually considered in the donor selection include presence of donor-specific antibodies in the recipient, donor age, donor/recipient gender and ABO combinations, and immunogenic variables, such as natural killer cell alloreactivity or KIR haplotype. Here we provide a comprehensive review of available evidence for selecting haploidentical donors for transplantation, and summarize the recommendations from the European Society for Blood and Marrow Transplantation (EBMT) on donor selection for different transplant platforms.

AB - The number of HLA-haploidentical hematopoietic cell transplants continues to increase worldwide due to recent improvements in outcomes, allowing more patients with hematological malignancies and non-malignant disorders to benefit from this procedure and have a chance to cure their disease. Despite these encouraging results, questions remain as multiple donors are usually available for transplantation, and choosing the best HLA-haploidentical donor for transplantation remains a challenge. Several approaches to haploidentical transplantation have been developed over time and, based on the graft received, can be grouped as follows: T-cell depleted haploidentical transplants, either complete or partial, or with T-cell replete grafts, performed with post-transplant cyclophosphamide-based graft-versus-host disease (GVHD) prophylaxis, or G-CSF-primed bone marrow graft and enhanced GVHD prophylaxis. Carefully selecting the donor can help optimize transplant outcomes for recipients of haploidentical donor transplants. Variables usually considered in the donor selection include presence of donor-specific antibodies in the recipient, donor age, donor/recipient gender and ABO combinations, and immunogenic variables, such as natural killer cell alloreactivity or KIR haplotype. Here we provide a comprehensive review of available evidence for selecting haploidentical donors for transplantation, and summarize the recommendations from the European Society for Blood and Marrow Transplantation (EBMT) on donor selection for different transplant platforms.

U2 - 10.1038/s41409-019-0499-z

DO - 10.1038/s41409-019-0499-z

M3 - Review article

C2 - 30833742

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

ER -